DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Lessons Learned from Drug Development Programs in Autism: Implications for Future Programs

Innov Clin Neurosci. 2026;23(4–6):9–16. Epub ahead of print. by Gahan Pandina, PhD; William J. Martin, PhD; Christopher Chatham, PhD; Declan Murphy, MD; Jane Myles, MSc; Robert H. Ring, PhD; and

Part 2—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the neuropsychiatric effects and dyskinesia that patients may experience when taking Vyalev (foscarbidopa/foslevodopa).
Part 1—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the safety profile of Vyalev (foscarbidopa/foslevodopa), notably injection site reactions and skin considerations.
January-March 2026 Digital Edition

Click the cover below to access the January-March 2026 Digital Edition

Letters to the Editor: Post-SSRI Sexual Dysfunction: Challenges and Treatment Approaches

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: Selective serotonin reuptake inhibitors (SSRIs) have long been a cornerstone in the treatment of mood disorders, particularly depression and anxiety. Since their introduction in

Letters to the Editor: Response to “Burnout and Ethical Awareness in Mental Health Professionals: A Correlational Study”

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: We read with great interest the study by Fatima and Ilyas,1 which explores the relationship between ethical awareness and burnout among mental health professionals